Abstract Body

Background:

Long-term exposure to three-drug regimens has been associated with toxic effects such as renal and bone toxicity related to tenofovir (TDF), cardiovascular and metabolic disorders for other ITRN. Since 2019, to minimize toxicity, Brazil recommends two-drug regimens (2-DRs) (3TC+DTG or 3TC+DRVr) for those already on antiretroviral therapy (ART), with undetectable viral load (VL) and for whom the use of tenofovir is contraindicated. Using real life data, we aimed to describe 2-DRs user profile and analyze the virological response among people living with HIV (PLHIV) in use of dual-therapy.

Methods:

We obtained MoH electronic records, from 2019 to 2021, on ART prescription, HIV viral load (VL) and demographic (age, sex, geographic region and ethnicity) data. We used descriptive statistics to quantify the use of 3TC+DTG and 3TC+DRVr and access VL suppression during HIV dual-therapy.

Results:

From 2019 to 2021, 22,401 PLHIV used 3TC+DTG or 3TC+DRVr regimens, of which 99% were ART-experienced. Of those starting 3TC+DTG, 72% was previously using DTG-containing regimens; while among those starting 3TC+DRVr, 50% was taking DRVr-based ART. Undetectable VL (VL ≤ 49 copies/mL) before starting 2-DRs was observed in 96% in 2019, 97%, in 2020 and 99%, in 2021. Up to 94% of those under 2-DRs were 30 years or older, 50% white/yellow, 29% black, and 58% lived in the Southeast region. Sex ratio (M/F) raised from 1.8 in 2019 to 2.0, in 2021. 3TC+DTG regimen was the preferred choice, representing 72% of first 2-DRs dispensations in 2019, and 91% in 2021. From 2019 to 2021, viral suppression raised from 92% to 97% when in use of 3TC+DTG; and 85% to 93%, for 3TC+DRVr.

Conclusions:

Dual-therapy regimens containing 3TC plus DTG or DRVr given to ART-experienced PLWHIV, with undetectable VL, provides a reasonable option for simplifying regimens, reaching satisfactory levels of viral suppression. This study further illustrates how monitoring of HIV care indicators is an effective way to validate and/or qualify health policies to guarantee proper health care for PLWHIV.